C7B.09 ICD-10-CM Code: Secondary carcinoid tumors of other sites
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Secondary neuroendocrine tumors (C7B)
C7B.09
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceSecondary carcinoid tumors of other sites
This code describes cancer that has spread to various parts of the body from a carcinoid tumor (a slow-growing neuroendocrine cancer) that originated elsewhere. Carcinoid tumors produce hormones that can cause specific symptoms like flushing and diarrhea.
Buddy Insight
Secondary carcinoid tumors of other sites represents metastatic carcinoid disease at locations not captured by the specific C7B codes (liver, bone, lymph nodes, peritoneum).
CMS-HCC V28
MappedHCC 17
RAF 0.368
CMS-HCC V24
MappedHCC 8
RAF 2.484
ACA/HHS
00
RAF 0
ESRD/PACE
MappedHCC 8
RAF 0.0
RXHCC
MappedHCC 18
RAF 0.0
Code Trumping
Basket needed
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for C7B.09 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C7B.09 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C7B.09 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for C7B.09 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C7B.09 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C7B.09 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C7B.09 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.
Is C7B.09 an HCC code?
Yes. C7B.09 maps to Metastatic Cancer and Acute Leukemia under the CMS-HCC V28 risk adjustment model (and Metastatic Cancer and Acute Leukemia under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C7B.09
For C7B.09to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C7B.09 during that encounter, not just copy-forwarded from a problem list.
What This Code Means
C7B.09 is the ICD-10-CM diagnosis code for secondary carcinoid tumors of other sites. This code describes cancer that has spread to various parts of the body from a carcinoid tumor (a slow-growing neuroendocrine cancer) that originated elsewhere. Carcinoid tumors produce hormones that can cause specific symptoms like flushing and diarrhea. C7B.09 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering secondary neuroendocrine tumors (c7b).
Under the CMS-HCC V28 risk adjustment model, C7B.09 maps to Metastatic Cancer and Acute Leukemia (HCC 17) with a community, non-dual, aged base RAF weight of 0.368. Under the older V24 model, C7B.09 mapped to the same category but with a base RAF weight of 2.484, V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code only for metastatic carcinoid tumors at sites other than the appendix, ileum, lung, thymus, stomach, or kidney—those have their own specific codes. Because C7B.09 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C7B.09 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Use this code only for metastatic carcinoid tumors at sites other than the appendix, ileum, lung, thymus, stomach, or kidney—those have their own specific codes
- •Always code the primary carcinoid tumor site first, then use C7B.09 as a secondary diagnosis to indicate spread to other locations
Clinical Significance
Secondary carcinoid tumors of other sites represents metastatic carcinoid disease at locations not captured by the specific C7B codes (liver, bone, lymph nodes, peritoneum). This includes metastases to the brain, skin, adrenal glands, ovaries, or other uncommon sites. Any metastatic carcinoid spread significantly impacts prognosis and treatment intensity, warranting systemic therapy and specialized multidisciplinary management.
Documentation Requirements
- ✓Documentation confirming metastatic carcinoid at the specified site
- ✓Primary carcinoid tumor site documented and coded separately
- ✓Specific metastatic site documented clearly in the medical record
- ✓Confirmation that the site does not fit C7B.01-C7B.04 (lymph nodes, liver, bone, peritoneum)
- ✓Imaging or pathology confirming carcinoid histology at the metastatic site
- ✓Treatment plan for the metastatic disease
Commonly Confused Codes
- •C7B.01-C7B.04 — Site-specific secondary carcinoid codes: Use these when the metastatic site is lymph nodes, liver, bone, or peritoneum
- •C7B.00 — Secondary carcinoid tumors, unspecified site: Use when the metastatic site is unknown; C7B.09 is for a known but non-standard site
- •C79 series — Secondary malignant neoplasm of other specified sites: Use for non-carcinoid metastatic cancers